BUY Fortis Healthcare — Jefferies India, 03 Sept 2026

byJefferies IndiaHorizon: NA (inferred 1 year)3 Sept 2026via Financial Express Market

Entry₹913.35Inferred

Target₹1,125

Stop lossNot given

CMP₹9052d ago

Active-0.91%+24.31%upside left 12 mo left

Follow Jefferies India for new calls(100% target hit, 27 closed calls)Get alerts Watch FORTIS for new buy/sell callsGet alerts See 15 other Long-term calls on FORTIS

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:04 am IST

13 supporting8 neutral3 opposing

Supports the BUY call (13)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

Fortis Healthcare shares rise as IHH Healthcare reiterates plans to increase stake

NewsCnbc-Tv18·28 Aug · 1w ago

Jefferies Spots A New Growth Trigger For Max Healthcare, Fortis, Medanta In Delhi's 2047 Master Plan

NewsGoogle News·25 Aug · 2w ago

Fortis Healthcare shares gain 2.52%, trades at Rs 929.00

NewsGoogle News·14 Aug · 3w ago

10 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·12 Aug · 4w ago

Neutral / worth noting (8)

Fortis Healthcare Success Story: Rise, Fall & Revival Explained

NewsGoogle News·22 Aug · 2w ago

Fortis Healthcare Share Price and Healthcare Sector View

NewsGoogle News·14 Aug · 3w ago

Weighs against the BUY call (3)

Fortis Healthcare reviews Delhi HC ruling in Daiichi Sankyo case, may approach Supreme Court

NewsEt-Markets·2 Sept · 5d ago

Fortis Healthcare shares fall 2.12%, trades at Rs 909.35

NewsGoogle News·17 Aug · 3w ago

Fortis Healthcare Shares Decline Over 2%; Stock Among Top Losers on Nifty Midcap 150

NewsGoogle News·12 Aug · 4w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.